clinical trial · NCT05113251
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
Breast NeoplasmsBreast CancerHER2-positive Early Breast CancerTrastuzumab DeruxtecanPaclitaxelTrastuzumabPertuzumabDoxorubicincyclophosphamide
brief summary
This study will look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast cancer.
started
Oct 25, 2021
primary completion
Mar 12, 2025
completion
Apr 30, 2027
last updated
Jun 9, 2026
detailed description
The target population of interest in this study is participants with high-risk HER2-positive early-stage breast cancer. The purpose of this study is to determine the efficacy and safety of T-DXd neoadjuvant therapy.
Participants will be randomised to one of 3 arms: T-DXd monotherapy (Arm A), T-DXd followed by THP (Arm B), or ddAC-THP (Arm C).
official title
A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd Followed by THP Compared to ddAC-THP in Participants With High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol